Brief: PharmAbcine Reports Collaboration with MSD for Phase II study in mTNBC
19/04/2021 14:32
April 19 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH
MSD FOR
THE PHASE II STUDY IN MTNBC
* PHARMABCINE - AGREEMENT WITH MSD TO INITIATE A PHASE II
COMBINATION TRIAL OF OLINVACIMAB AND KEYTRUDA IN METASTATIC
TRIPLE-NEGATIVE BREAST CANCER
* PHARMABCINE - CO WILL SPONSOR A PHASE II CLINICAL TRIAL
THAT
WILL TAKE PLACE IN BOTH AUSTRALIA AND SOUTH KOREA, AND MSD WILL
SUPPLY KEYTRUDA
Source text for Eikon: ID:nPn1Sxc5Sa
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration